Almirall, S.A. (0O9B.IL)
| Previous close | 9.60 |
| Open | 0.00 |
| Bid | 9.35 x 0 |
| Ask | 9.63 x 0 |
| Day's range | 9.56 - 9.58 |
| 52-week range | 7.76 - 10.08 |
| Volume | |
| Avg. volume | 7,828 |
| Market cap | 2.177B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (2.03%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Simply Wall St.
Almirall And Two Additional Stocks Considered Below Estimated Market Value
Amidst a complex landscape where global markets display mixed signals, investors are increasingly turning their attention to value and small-cap stocks. This shift comes as major indices like the Dow Jones Industrial Average see notable performance, highlighting a growing divergence from growth stocks which have recently underperformed. In such an environment, identifying undervalued stocks becomes crucial. These are shares that trade below what they are fundamentally worth, offering...
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
